STE · STERIS plc

Track STE — free

$236.91 +4.52 (+1.95%) At close · Aug 19

Market Cap

$22.74B

97.50M

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 11 wks

FQ2-27 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 7, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Moderate

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +1%

above

Price vs 50-day avg +8%

above

RSI (14) 61

neutral

MACD trend Negative

52-week position 54%

mid-range

Momentum

relative strength

Weak

1-month return +13%

trailing

6-month return −7%

trailing

YTD return −7%

this year

Relative strength −19%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $219 › 200d $234 — 200d above 50d

Institutional flow Distributing

-2% holders QoQ · +106 funds added

Insider flow Distributing

Net -$1.3M over 90 days · 100% sells

Short interest Rising

3.24% of float · ▲ +29.5% MoM · 4.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

825 holders — mid 3-yr range

Squeeze score 62

elevated · 0–100

Fundamentals

Excellent

Revenue growth +9%

Y/Y

Gross margin 44%

expanding

EPS growth +28%

Y/Y

Free cash flow $972.4M

Valuation P/E 29.4

below peers

Buyback $900.0M

remaining

Balance sheet $1.5B

net debt

Quant / Vol

risk profile

Moderate

Volatility 25%

annualized · 1-yr

Max drawdown −26%

past year

ATR 2.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 5, 2026

fiscal 2027

Adjusted earnings per diluted share Initiated $11.10 – $11.30

Free cash flow Initiated $800M

Capital expenditures Initiated $450M

fiscal 2030

Total pre-tax restructuring charges Initiated $55M – $70M

Non-cash charges Initiated $15M – $20M

Cash expenditures Initiated $40M – $50M

FY 2027

Free cash flow Initiated $800M

Adjusted net income from continuing operations per diluted share Initiated $11.10 – $11.30

Net income from continuing operations per diluted share Initiated $8.92 – $9.12

Prior guidance period ended · from the Earnings Call filed Dec 31, 2024

As-reported revenue from continuing operations · 2025 6%

Adjusted earnings per diluted share · 2025 $9.05 – $9.15

Constant currency organic revenue growth · 2025 6%

Free cash flow · 2025 $700M

Capital spending · 2025 $360M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+1% Bullish

Price vs 50-day avg

+8% Bullish

RSI (14)

61 Neutral

MACD trend

Negative Bearish

52-week position

54% Neutral

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $219 › 200d $234 — 200d above 50d

Institutional flow Distributing

-2% holders QoQ · +106 funds added

Insider flow Distributing

Net -$1.3M over 90 days · 100% sells

Short interest Rising

3.24% of float · ▲ +29.5% MoM · 4.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

825 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $199 Now $237 · 54% Range high $269

vs 200-day avg +1% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted Income Tax Rate non-GAAP	25.9%	Q1	—
AST Constant Currency Organic Growth non-GAAP	4.7%	Three Months Ended June 30	—
AST Organic Growth non-GAAP	5.8%	Three Months Ended June 30	—
Constant currency organic revenue growth non-GAAP	6%	the first quarter of fiscal 2027	—

Free cash flow non-GAAP	$279.6M	the first quarter of fiscal 2027	—
GAAP → non-GAAP reconciliation GAAP Cash flows from operating activities 367.1M -87.5M Purchases of property, plant, equipment, and intangibles, net +0M Proceeds from the sale of property, plant, equipment, and intangibles = Free Cash Flow 279.6M
Healthcare Backlog	$444M	Q1	—
Healthcare Constant Currency Organic Growth non-GAAP	6.4%	Three Months Ended June 30	—
Life Sciences Backlog	$109.9M	Q1	—
Life Sciences Constant Currency Organic Growth non-GAAP	7.9%	Three Months Ended June 30	—
Life Sciences Organic Growth non-GAAP	8.6%	Three Months Ended June 30	—
Total Backlog	$553.9M	Q1	—
Total Organic Growth non-GAAP	6.8%	Three Months Ended June 30	—
Adjusted EPS per diluted share non-GAAP	$10.17	full year fiscal 2026	—
Constant currency organic revenue growth from continuing operations non-GAAP	7%	full year fiscal 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
STE STERIS plc this stock	$22.74B	-6.6%	+8.7%	29.4	3.2%
ABT Abbott Laboratories	$196.27B	-8.7%	+5.7%	31.6	1.3%
SYK Stryker Corp	$127.34B	-3.3%	+11.2%	34.4	2.2%
MDT Medtronic plc	$115.97B	-2.0%	+8.4%	24.3	1.4%
BSX Boston Scientific Corp	$73.14B	-45.5%	+12.5%	20.4	1.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

825

% held: 97.1%
Net QoQ: +835.6K sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

281

View

Short & Settlement

Short Interest Rising

Shares short

3.2M

Days to cover: 4.5d
Change: +719.8K sh

View

Short Volume

Short vol %

61%

As of: Aug 19, 2026

Short Total

View

Fails to Deliver

FTD shares

1.2K

Value: $269.1K
As of: Jul 31, 2026

View

Off-Exchange

Off-exchange %

39.8%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$1.3M

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Congressional Trades Sell

Member

April McClain Delaney

Amount: $1.0K–$15.0K
Traded: Jul 31, 2026

View

Financials

Revenue (FY)

$5.9B

Net income (FY): $782.3M
EPS diluted: $7.93

View

Buybacks

Remaining

$900.0M

View

Filings

SEC Filings

Latest

10-Q

Filed: Aug 7, 2026
This year: 11

View

Proposed Sales

Value

$953.1K

Shares: 4.1K
Filed: Aug 18, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Performance

	5D	20D	120D	MTD	YTD
STE	+0.1%	+12.5%	-7.0%	+3.7%	-6.6%
SPY	-0.4%	+2.9%	+11.6%	+3.0%	+12.8%
vs SPY	+0.6%	+9.6%	-18.6%	+0.8%	-19.3%

Capital returns

Latest dividend

$0.63 / share · ex Jun 8, 2026

Declared · upcoming

$0.69 / share · ex Sep 4, 2026

Raised 10.5%

Paid (TTM)

$1.89 / share · 3 payouts

Dividend yield (TTM, derived)

0.80%

Buyback program · as of Jun 30, 2026

Authorized

—

Spent (derived)

—

Remaining

$900.00M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1757898 CUSIP G8473T100 13F (30d) 763 filings 721 filers Visit website Investor relations

STE · STERIS plc

Price & Indicators

Up next

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns